Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
CLDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.91 - $53.18
Previous CloseN/A
Volume733.18K
Average Volume (3M)959.00K
Market Cap
$1.50B
Enterprise Value$1.51B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 03, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding66,344,240
10 Day Avg. Volume756,037
30 Day Avg. Volume958,996
Standard Deviation0.53
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)149.90
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit388.57
Enterprise Value/Ebitda-8.80
Forecast
1Y Price Target
$70.20Price Target Upside204.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Clinical ProfileBarzolvolimab represents a best-in-class mast cell targeting agent with stellar efficacy and a consistent, acceptable safety profile across two large Phase 2 urticaria studies.
Efficacy In Eosinophilic EsophagitisClinical and commercial opportunity for barzolvolimab in eosinophilic esophagitis, aiming for efficacy on par or better than existing treatments with less-frequent dosing.
Market OpportunityCelldex's unique mast cell-depleting mechanism & attributes offer a differentiated, first-in-class/best-in-class profile that stands to unlock significant commercial opportunity in urticaria and other mast cell-driven diseases.
Bears Say
Competitive MarketThe results of a competitor’s study reinforce the analyst's view that barzolvolimab offers the most compelling clinical profile among agents in development for CSU.
Competitive PressureCLDX shares have been pressured due to competitive clinical data overhangs from competing early-stage agents.
Market Differentiation ChallengesBarzo has a viable opportunity as a mast cell depleting agent to differentiate in the competitive atopic dermatitis market.
---
Ownership Overview
0.36% Insiders
36.04% Mutual Funds
41.42% Other Institutional Investors
8.96% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLDX FAQ
What was Celldex Therapeutics Inc’s price range in the past 12 months?
Celldex Therapeutics Inc lowest stock price was $20.91 and its highest was $53.18 in the past 12 months.
What is Celldex Therapeutics Inc’s market cap?
Celldex Therapeutics Inc’s market cap is $1.50B.
When is Celldex Therapeutics Inc’s upcoming earnings report date?
Celldex Therapeutics Inc’s upcoming earnings report date is Mar 03, 2025 which is in 10 days.
How were Celldex Therapeutics Inc’s earnings last quarter?
Celldex Therapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$0.64 earnings per share for the quarter, beating the consensus estimate of -$0.673 by $0.033.
Is Celldex Therapeutics Inc overvalued?
According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued.
Does Celldex Therapeutics Inc pay dividends?
Celldex Therapeutics Inc does not currently pay dividends.
What is Celldex Therapeutics Inc’s EPS estimate?
Celldex Therapeutics Inc’s EPS estimate is -0.74.
How many shares outstanding does Celldex Therapeutics Inc have?
Celldex Therapeutics Inc has 66,344,240 shares outstanding.
What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?
Celldex Therapeutics Inc reported an EPS of -$0.64 in its last earnings report, beating expectations of -$0.673. Following the earnings report the stock price went down -4.198%.
Which hedge fund is a major shareholder of Celldex Therapeutics Inc?
Currently, no hedge funds are holding shares in CLDX
---
Celldex Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.20 (204.56% Upside)
$70.20 (204.56% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 78.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.73%
12-Months-Change
Fundamentals
Return on Equity
-29.84%
Trailing 12-Months
Asset Growth
193.72%
Trailing 12-Months
Company Description
Celldex Therapeutics Inc
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
---
CLDX Stock 12 Month Forecast
Average Price Target
$70.20
▲(204.56% Upside)
Technical Analysis
Best Analysts Covering CLDX
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+88.76%
reiterated a buy rating 24 days ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +88.76% per trade.
---